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Introduction: Sanfilippo syndrome type A (mucopolysaccharidosis IIIA - MPS IIIA) is an autosomal recessive
lysosomal storage disorder caused by a deficiency in sulfamidase.
Case presentation: Two daughters (13 and 11 years old) of a consanguineous Palestinian family from the Israeli
Arab community were investigated clinically and genetically for the presence of progressive neurodegenerative
disease, psychomotor retardation and behavioral abnormalities. Development was normal up to one year of age.
Thereafter, progressive motor and speech delay started. Metabolic screening including glycosaminoglycans,
karyotype testing and magnetic resonance imaging were normal. Later in the disease, they developed severe
spasticity and intellectual disability with autistic features and incontinence. Magnetic resonance imaging revealed
diffuse hypomyelination with thinning of the corpus callosum. Genetic examination through whole exome
sequencing revealed a homozygous mutation c.416C >T (p.T139M) in the N-sulfoglucosamine sulfohydrolase (SGSH)
gene. Repeated biochemical testing at age 11 and 13 revealed increased levels of glycosaminoglycans confirming
the diagnosis of Sanfilippo syndrome type A.
Conclusion: These cases were considered to be the first report of Sanfilippo syndrome in Israel. We recommend
that if similar clinical features are present during childhood, it is preferred to go directly and primarily for a genetic
diagnosis of Sanfilippo syndrome, then secondarily for other lysosomal storage disorders that may also be involved.
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The mucopolysaccharidoses (MPSs) are a group of seven
inherited metabolic disorders characterized by the defi-
ciency of one of the lysosome enzymes catalyzing the
degradation of glucosaminoglycans (GAG) or mucopoly-
saccharides [1,2]. This deficiency leads to abnormal
accumulation of GAG in the lysosomes which in turn
gets excreted in the urine. GAG accumulation results
in physical and mental handicap [3]. Mucopolysaccharido-
sis type III (MPS III) is known as Sanfilippo syndrome.* Correspondence: rajachsharkia@hotmail.com; ludger.schoels@uni-tuebingen.de
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unless otherwise stated.It shows autosomal recessive inheritance and is caused
by a deficiency of one of four enzymes involved in the
degradation of the glucosaminoglycan heparan sulfate
[4]. According to the defective enzyme, four subtypes
of MPS III are designated as type A, B, C and D. The
frequency of these subtypes varies between 0.28 and
4.1 per 100,000 live births [5]. It was found that Sanfilippo
syndrome type A (MIM 252900) was the most frequent
subtype accounting for 1 in 114,000 live births [6]. It is
caused by a deficiency of the enzyme sulfamidase (heparan
N-sulfatase), that degrades heparan sulfate; this causes
an increase in the urinary excretion of heparan sulfate.
Two biochemical tests were employed for MPS III diag-
nosis: (i) measuring the concentration of GAGs in urine,
and (ii) measuring the enzyme activity in leucocytes or
cultured fibroblasts [7,8]. The gene encoding sulfamidaseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 (A): Patient 1, clear skin discolorization, (B): Patient 2,
mild pes cavus and skin discolorization.
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chromosome 17, spans 11kb, contains 8 exons and encodes
a protein of 502 amino acids [9]. There are 115 disease-
causing SGSH mutations reported so far [1].
Clinical features and disease severity in patients with
Sanfilippo syndrome type A vary considerably. A com-
prehensive study describing the clinical features of 92
patients suffering from MPS IIIA found a wide phenotypic
variability and revealed a significant genotype and/or
phenotype correlation [4].
As a part of a study on genetic diseases in consanguineous
families of the Arab community in Israel, we investigated
two patients with developmental delay starting between
the first and the second year of life and progressing to
severe psychomotor handicap at 10 years of age. Since
extensive work-up, including glycosaminoglycans, was
negative, diagnosis of Sanfilippo syndrome type A was
only made by next-generation whole exome sequencing. To
the best of our knowledge, the two patients in our study
were the first Israeli cases to be reported in the literature.
Case presentation
This research was prospectively reviewed and approved
by the ethics committee in our center. Two siblings of a
consanguineous Palestinian family from the Israeli Arab
community attended the child development and pediatric
neurology clinic due to progressive psychomotor retard-
ation and behavioral difficulties.
Patient 1
Our first patient is a 13-year-old girl who was born to
consanguineous parents (first degree cousins) after a full
term pregnancy by cesarean section delivery due to mater-
nal hypertension, pre-eclampsia and breech presentation
with a normal birth weight of 3.3Kg. According to her
parents, she had normal development till the age of
one year. She was first referred to a pediatric neurology
clinic at the age of 18 months for suspected motor delay.
At this time, her examination revealed no dysmorphic fea-
tures and no visceral enlargement. She showed mild motor
delay but could stand with support, and could speak up to
five words. Her neurologic examination revealed hypertonia
of the lower extremities and increased tendon reflexes of
the lower and upper limbs. The Babinski sign was flexor.
Cranial nerves, sensory perception and cerebellar function
were normal. She was referred for metabolic screening, in-
cluding glycosaminoglycans in the urine (u-GAGs), which
was normal. Furthermore, karyotype testing and brain mag-
netic resonance imaging (MRI) were carried out at the age
of two years and found to be normal. She also underwent
cerebrospinal fluid examination for protein, glucose, lactate
levels and cell count yielding normal results.
She was further followed-up by the pediatric neurology
and child development clinic. At the age of three years,a second u-GAGs screening was performed and found to
be normal. At the age of 11 years, she started to suffer from
recurrent convulsions; paroxysmal events of generalized
hypertonia, and absences with loss of consciousness for
several minutes. The electroencephalography (EEG) record
was normal but she was treated with valporic acid with
good response. At the age of 12 years, her neurologic signs
were progressive, including severe spasticity, impaired
dexterity and severe intellectual disability with autistic fea-
tures and incontinence. She also had hearing impairment
(auditory evoked potentials were abnormal on both sides),
joint contractures, pes cavus, and skin discoloration of the
arms, hands, legs and feet (Figure 1). A second brain MRI
revealed parieto-occipital atrophy, including cortex atro-
phy, thin corpus callosum, white matter thinning and mild
ventriculomegaly (Figure 2).
Patient 2
The second patient is an 11-year-old girl, who is the
younger sister of Patient 1. She was born after a full
term pregnancy by cesarean section delivery due to mater-
nal hypertension, pre-eclampsia and breech presentation
with normal birth weight (3.0Kg). According to her parents,
her development was normal until the age of 18 months.
Then she was referred to pediatric neurology for sus-
pected motor and speech delay. At this age, her examin-
ation revealed neither dysmorphic features nor visceral
Figure 2 (A, B, C): Magnetic resonance imaging of Patient 1, diffuse hypomyelienation, thinning of the carpus callosum and moderate
cerebral atrophy.
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Her neurologic examination revealed similar findings to
her elder sister with hypertonia of the lower extremities
and increased tendon reflexes of upper and lower limbs.
Babinski sign was negative. Cranial nerves, sensory reac-
tions and cerebellar function were normal. Metabolic
screening including u-GAGs was normal. Furthermore,
karyotype testing and cerebrospinal fluid examination
for protein, glucose, lactate levels and cell count yielded
normal results.
She continued to deteriorate with progression of neuro-
logic symptoms and developmental deficits. At age 11 years
she presented with similar findings as her elder sister,
including severe spasticity, impaired dexterity and se-
vere intellectual disability with autistic features, joint
contractures, pes cavus, and skin discoloration of the
arms, hands, legs and feet (Figure 1). Brain MRI revealed
similar findings as in Patient 1, including diffuse hypomyeli-
nation with thinning of the corpus callosum.
In light of these findings, genetic tests were sought by
the parents for family planning purposes. Homozygosity
mapping was undertaken by single nucleotide polymorph-
ism (SNP) microarray genotyping (Illumina 6k human
mapping array, Illumina, San Diego, CA, USA) in both
affected siblings and the parents. Eight regions of shared
homozygosity in the two sibs spanning 84MB in total
were revealed. Exome sequencing (NimbleGen SeqCap
V2, Roche, Mannheim, Germany) followed by Illumina
GAIIx paired-end sequencing for 2×76bp (Illumina, San
Diego, CA, USA) uncovered a homozygous mutation
c.416C > T, p.T139M in the SGSH gene causing mucopo-
lysaccharidosis type IIIA, that is, Sanfilippo A syndrome.
This mutation has already been discussed in a published
article [10]. A third u-GAG test was performed, which
revealed an increased level of u-GAGs, thus, confirming
the genetic results.
Discussion
There are four subtypes of mucopolysaccharidosis III
(MPS III = Sanfilippo syndrome), namely A, B, C and D,that are caused by deficiency of one of four lysosomal
enzymes, respectively. All are inherited by an autosomal
recessive trait; signs, symptoms and the course of the
disease in the different subtypes are indistinguishable.
Therefore, misdiagnosis of the various subtypes often
occurs [11]. MPS IIIA is caused by a deficiency of the
enzyme sulfamidase due to SGSH mutations, which is
involved in the stepwise degradation of heparan sul-
fate. SGSH is characterized by the presence of multiple
polymorphisms [9].
The summary of clinical signs and symptoms in our
reported cases, compared with other patients described
in previous studies [1,4,5] are presented in Table 1. Most
of the MPS IIIA symptoms found in our patients were
similar to the described patients. These include normal
development until one year of age followed by delay of
motor and speech development as well as behavioral
problems and facial dysmorphisms. According to the
clinical progression, severe, intermediate and attenuated
courses are differentiated. The clinical features of our
two patients indicated a severe course, based on their
full dependence on external care, complete loss of ini-
tiative and restriction to wheelchairs. However, other
patients with Sanfilippo type A had even more rapid
progression of symptoms [5].
Between the age of 10 and 11 years: autistic-like behaviors
(according to Diagnostic and Statistical Manual of Mental
Disorders (DSM) IV criteria), were found in both our pa-
tients. This symptom was not observed in a large series of
MPS IIIA [4] but was described in our patients at the age
of three to four years in another study [11]. On the other
hand, some previously described clinical symptoms like
hepatomegaly, recurrent diarrhea and recurrent ear, nose
and/or throat (ENT) infections [4], were not observed in
our patients. Furthermore, we observed pes cavus and skin
discoloration in our patients that were not reported before
in patients with Sanfilippo syndrome type A. Both signs
may be caused by neurodegeneration due to the production
of neurotoxic substances [12]. It was previously noted that
evolving joint pain and joint contractures in the absence of
Table 1 Comparing symptoms of Sanfilippo type A as described in the literature [1,3,4] with our patients
Clinical features Reported phenotype Patient-1 Patient-2
Pregnancy and delivery
complications:
35 to 43 weeks, birth weight: 3534g, maternal
hypertension, mild bleeding, normal delivery
for majority of patients.
Normal pregnancy, birth weight:
3300g, delivery by caesarean section,
maternal hypertension, pre-eclampsia
and breech presentation.
Normal pregnancy, birth weight:





Normal development until one year, later
on developmental and speech delay with
behavioral problems.
Normal development until one year,
later on motor and speech delay.
Normal development until 1.5 years,
later on motor and speech delay.
Facial dysmorphisms. Negative. Negative.
Hepatomegaly. Negative. Negative.
Recurrent diarrhea. Negative. Negative.
Recurrent ear, nose and/or throat
(ENT) infections.
Negative. Negative.
Age of diagnosis: Median age of 4 years (range 2 to 47 years). 12 years. 10 years.
Behavioral problems: Before 10 years of age: restlessness, temper
tantrum, crying fits, hyperactivity, destructive
and compulsive behavior and complete loss
of initiative in the majority of patients.
At age three to four years:
restlessness.
At age three to four years:
restlessness.
At age 10 to 11 years: complete loss
of initiative with autistic-like behavior.
At age 10 to 11 years: complete loss
of initiative with autistic-like behavior.
Sleeping problems: Onset at a median age of 4 years (range 0
to 35 years) with difficulties of falling
asleep and frequent nocturnal wakening.
No sleep disturbance. No sleep disturbance.
Hearing problems: Present in about 40% of patients. Moderate to severe sensory bilateral
hearing loss; abnormal auditory
potentials (BAER).
Moderate to severe sensory bilateral
hearing loss; abnormal auditory
potentials (BAER).
Visual problems: Formal visual testing not possible. Formal visual testing not possible. Formal visual testing not possible.
Fundoscopy: Retinitis pigmentosa one-third of patients
older than 21 years.
Normal. Normal.
Epilepsy: About 66% developed epilepsy at a median
age of 11 years (range 1 to 43 years), but
well controlled by medication.
Onset of epileptic seizure at the age
of 11 years but well controlled
by valproic acid.
None.
Age at death: Median 18 years (range 6 to 59). Current age 13 years. Current age 11 years.
Joint contractures: Present. Present. Present.
Scoliosis: Present. Present. Present.
Kyphosis: Present. Present. Present.
Pes cavus: Not described. Present. Present.
Skin discoloration: Not described. Present. Present.
Dysmorphic features: Present. Obvious at 10 to 11 years of age. Obvious at 10 to 11 years of age.
Magnetic resonance
imaging (MRI) findings:
Not reported. Diffuse hypomyelination, thin
corpus callosum and progressive
cerebral atrophy.
Diffuse hypomyelination and thin
corpus callosum.
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disorder [13]. Additionally, both patients were born
after complicated pregnancy with hypertension and pre-
eclampsia. Previously, it was reported that only 6 cases
from 76 Sanfilippo A patients were born after complicated
pregnancy, such as hypertension and mild bleeding, but
pre-eclampsia was not reported [4].
Mucopolysaccharidosis III disease is characterized by
an inability to degrade heparan sulfate that leads to its
excretion in the urine. The assay of urine-GAG is usu-
ally the first step in biochemical diagnosis of this disease.
U-GAG testing is easy to perform but it remains unreliablein the diagnosis of MPS III. Among the MPSs, patients with
MPS III have comparatively lower levels of u-GAG, leading
to some risk of false-negative results [14]. With respect
to this problem, u-GAGs were determined twice in our
patients but both times with normal results. Only the
third test, after genetic diagnosis, revealed that u-GAG
levels were higher than normal. Recently, it was found
that urinary levels of heparan sulfate among patients
with attenuated MPS IIIA are substantially lower than
that in patients with severe MPS IIIA [15]. However,
our patients had normal urinary heparan sulfate long
into the disease despite a severe course of MPS IIIA. Thus,
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not rule out the diagnosis of MPS III.
MRI revealed progressive parieto-occipital atrophy,
including cortex atrophy, thin corpus callosum white
matter thinning due to diffuse hypomyelination in our
patients. These findings were not previously described
in patients with type A of Sanfilippo syndrome but only
in other Sanfilippo subtypes [3]. Neuronal degeneration is
probably a late phenomenon, as cortical atrophy was not
observed in the early MRI scans in our patients [16].
Recently, a therapeutic approach to Sanfilippo disease
has been proposed. Genistein is a naturally occurring
isoflavone and inhibits heparan sulfate synthesis in cultured
fibroblasts from MPS III patients. Genistein treatment
reduced plasma levels of heparan sulfate as well as
urinary GAG excretion but failed to ameliorate clinical
disease in Sanfilippo patients in a placebo-controlled
crossover study [17]. Higher dosage may be more efficient
but controlled trials have to be awaited. They should also
help to clarify whether response to Genistein is dependent
on the stage of the disease.
The mutation found in our patients (p.T139M) was
described previously as a cause of MPS IIIA in a patient
from the UK but no clinical description was reported
[10]. Here we show that the T139M mutation in SGSH
can cause a severe phenotype and does occur in the Arab
population of Israel.
As the parents insisted on having a healthy child, and
due to their status quo as a consanguineous couple, it
was inevitable to refer them to a genetic counseling unit
and the PGD (pre-gestational diagnosis) clinic. Previous
studies confirmed the correlation between the high
prevalence of autosomal recessive genetic disorders and
the high rate of consanguineous marriages in the Arab
population [18].
Conclusion
This study is considered to be the first report that described
two patients with Sanfilippo syndrome in Israel. While the
biochemical testing proved to be misleading for the proper
diagnosis of Sanfilippo syndrome, it is recommended that if
similar clinical features are present during childhood, it is
preferred for the patients to go directly and specifically for
genetic diagnosis of Sanfilippo syndrome, though, other
lysosomal storage disorders may also be involved. Further-
more, MRI imaging revealed diffuse hypomyelination with
thinning of the corpus callosum that might be associated
with this syndrome.
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